New 'Living Drug' trial targets Tough-to-Treat blood cancers
Disease control
Terminated
This early-stage trial tested a new type of personalized cell therapy for adults with acute myeloid leukemia (AML) that has come back or hasn't responded to other treatments. Doctors modified patients' own immune cells (T-cells) to target a protein called CD123 found on cancer ce…
Phase: PHASE1 • Sponsor: AvenCell Europe GmbH • Aim: Disease control
Last updated Mar 11, 2026 14:54 UTC